NYSE:RCUSArcus Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcus Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.44 -0.45 (-3.02 %) (As of 04/5/2020 02:21 PM ET) Add Compare Share Today's Range$14.18Now: $14.44▼$15.2550-Day Range$10.00MA: $14.50▼$19.2852-Week Range$6.30Now: $14.44▼$20.40Volume158,034 shsAverage Volume377,031 shsMarket Capitalization$663.81 millionP/E RatioN/ADividend YieldN/ABeta-0.21 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.80, Arcus Biosciences has a potential upside of 44.0% from its current price of $14.44.Amount of Analyst CoverageArcus Biosciences has only been the subject of 4 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesArcus Biosciences has received 126 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArcus Biosciences has received 139 “underperform” votes. (Add your “underperform” vote.)Community SentimentArcus Biosciences has received 52.45% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote “Outperform” if you believe RCUS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 19.23% of the stock of Arcus Biosciences is held by insiders.Percentage Held by Institutions47.98% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to grow by 29.22% in the coming year, from ($2.19) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is -7.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.61 out of 5 stars Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS Previous Symbol CUSIPN/A CIK1724521 Webhttp://www.arcusbio.com/ Phone510-694-6200Debt Debt-to-Equity RatioN/A Current Ratio8.49 Quick Ratio8.49Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15 million Price / Sales44.25 Cash FlowN/A Price / Cash FlowN/A Book Value$3.57 per share Price / Book4.04Profitability EPS (Most Recent Fiscal Year)($1.93) Net Income$-84,710,000.00 Net Margins-564.73% Return on Equity-44.63% Return on Assets-36.93%Miscellaneous Employees108 Outstanding Shares45,970,000Market Cap$663.81 million Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive RCUS News and Ratings via Email Sign-up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. RCUS Rates by TradingView Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions How has Arcus Biosciences' stock been impacted by COVID-19 (Coronavirus)? Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RCUS shares have decreased by 14.9% and is now trading at $14.44. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Arcus Biosciences? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arcus Biosciences. When is Arcus Biosciences' next earnings date? Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Arcus Biosciences. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences Inc (NYSE:RCUS) issued its earnings results on Thursday, March, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.51) by $0.13. The business had revenue of $9.75 million for the quarter, compared to the consensus estimate of $1.37 million. Arcus Biosciences had a negative return on equity of 44.63% and a negative net margin of 564.73%. View Arcus Biosciences' earnings history. What price target have analysts set for RCUS? 6 brokerages have issued twelve-month target prices for Arcus Biosciences' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate Arcus Biosciences' stock price to reach $20.80 in the next twelve months. This suggests a possible upside of 44.0% from the stock's current price. View analysts' price targets for Arcus Biosciences. Has Arcus Biosciences been receiving favorable news coverage? News stories about RCUS stock have been trending very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arcus Biosciences earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutArcus Biosciences. Are investors shorting Arcus Biosciences? Arcus Biosciences saw a drop in short interest in March. As of March 13th, there was short interest totaling 948,200 shares, a drop of 37.6% from the February 27th total of 1,520,000 shares. Based on an average daily trading volume, of 247,400 shares, the short-interest ratio is currently 3.8 days. Currently, 2.9% of the shares of the stock are short sold. View Arcus Biosciences' Current Options Chain. Who are some of Arcus Biosciences' key competitors? Some companies that are related to Arcus Biosciences include Arrowhead Pharmaceuticals (ARWR), GW Pharmaceuticals PLC- (GWPH), Agios Pharmaceuticals (AGIO), Amicus Therapeutics (FOLD), ChemoCentryx (CCXI), ArQule (ARQL), PPD (SDGR), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ra Pharmaceuticals (RARX), Alkermes (ALKS), Allakos (ALLK), Arena Pharmaceuticals (ARNA), Myokardia (MYOK) and Deciphera Pharmaceuticals (DCPH). What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Agile Therapeutics (AGRX), Amarin (AMRN), Crispr Therapeutics (CRSP), Sorrento Therapeutics (SRNE), Aduro BioTech (ADRO), Anavex Life Sciences (AVXL), Nabriva Therapeutics (NBRV) and VBI Vaccines (VBIV). Who are Arcus Biosciences' key executives? Arcus Biosciences' management team includes the following people: Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)Mr. Steven Chan, Consultant (Age 47)Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)Dr. Stephen Young Ph.D., VP of Technology (Age 50) When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." How do I buy shares of Arcus Biosciences? Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $14.44. How big of a company is Arcus Biosciences? Arcus Biosciences has a market capitalization of $663.81 million and generates $15 million in revenue each year. The company earns $-84,710,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe. View additional information about Arcus Biosciences. What is Arcus Biosciences' official website? The official website for Arcus Biosciences is http://www.arcusbio.com/. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Hedge Funds - How They Work For Investors
